Introduction & Objective: A healthy reserve of functional β-cells is crucial for maintaining glucose homeostasis and is disrupted in diabetes. Most of this reserve is established in early neonatal life via replication, following which β-cells exit cell-cycle and undergo functional maturation. Although the process of replication is extremely vulnerable to DNA damage and consequent genomic instability, the extent and impact of such vulnerabilities on β-cell maturation and subsequent viability is not clear. Here, we sought to determine the DNA damage vulnerability of replicating β-cells in the neonatal growth phase.

Methods: We quantified β-cell replication (Ki67, pHH3) and DNA damage (ɣH2AX) in early (p7) and late (p21) neonatal B6 mice (N=8 animals/ group). We acquired super-resolution 3D images of DNA damage foci and cohesins (modulators of genomic stability) in replicating β-cells using the Zeiss Elyra 7 Lattice SIM^2 and LSM880 with Airyscan, and analyzed using the Imaris software.

Results: Our data revealed that while the overall number of β-cells with DNA damage decreased as replication declined from p7 to p21, ~20% of replicating β-cells at each stage harbored DNA damage. Notably, the G2 phase had the highest density of DNA damage foci, which were resolved by the M phase. Single-cell RNA-seq of murine neonatal islets showed the enrichment of DNA damage repair pathways in replicating β-cells.

Conclusion: Collectively, our data establish the high DNA damage vulnerability of neonatal β-cells and suggest the existence of robust mechanisms that assist the resolution of DNA damage with cell cycle progression to maintain genomic stability.

Disclosure

S.S. Varghese: None. A.G. Hernandez-De La Pena: None. S. Bhattacharya: None. S. Dhawan: None.

Funding

Postdoctoral Fellowship from California Institute of Regenerative Medicine (EDU4-12772); NIH-National Institute of Diabetes and Digestive and Kidney Diseases (R01DK120523)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.